Transcenta Holding Limited

SEHK:6628 Stok Raporu

Piyasa değeri: HK$409.1m

Transcenta Holding Yönetim

Yönetim kriter kontrolleri 3/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

Xueming Qian

İcra Kurulu Başkanı

CN¥5.6m

Toplam tazminat

CEO maaş yüzdesi20.3%
CEO görev süresi12.1yrs
CEO sahipliği12.7%
Yönetim ortalama görev süresi2.8yrs
Yönetim Kurulu ortalama görev süresi3.2yrs

Son yönetim güncellemeleri

Recent updates

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

Dec 15
Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

CEO Tazminat Analizi

Xueming Qian'un ücretlendirmesi Transcenta Holding'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-CN¥359m

Mar 31 2024n/an/a

-CN¥411m

Dec 31 2023CN¥6mCN¥1m

-CN¥463m

Sep 30 2023n/an/a

-CN¥451m

Jun 30 2023n/an/a

-CN¥440m

Mar 31 2023n/an/a

-CN¥424m

Dec 31 2022CN¥6mCN¥1m

-CN¥407m

Sep 30 2022n/an/a

-CN¥666m

Jun 30 2022n/an/a

-CN¥925m

Mar 31 2022n/an/a

-CN¥2b

Dec 31 2021CN¥5mCN¥1m

-CN¥2b

Sep 30 2021n/an/a

-CN¥1b

Jun 30 2021n/an/a

-CN¥1b

Mar 31 2021n/an/a

-CN¥364m

Dec 31 2020CN¥51mCN¥1m

-CN¥317m

Dec 31 2019CN¥14mCN¥823k

-CN¥395m

Tazminat ve Piyasa: Xueming's total compensation ($USD781.03K) is above average for companies of similar size in the Hong Kong market ($USD234.60K).

Tazminat ve Kazançlar: Xueming's compensation has been consistent with company performance over the past year.

CEO

Xueming Qian (55 yo)

12.1yrs

Görev süresi

CN¥5,562,000

Tazminat

Dr. Xueming Qian, Ph.D. has been Chief Executive Officer and Executive Director at Transcenta Holding Limited and serves as its Chairman since June 07, 2024. He was the Founder, Chairman and Chief Executiv...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Xueming Qian
CEO & Executive Chairmanno dataCN¥5.56m12.71%
HK$ 52.0m
Xiaolu Weng
Executive VP & CFO2.9yrsCN¥8.32mVeri yok
Christopher Hwang
Executive VP of Process Development & CTO5.8yrsVeri yokVeri yok
Wei Wang
VP of Investor Relations & Capital Markets Department and Secretary to the Board2.7yrsVeri yokVeri yok
Yi Gu
Senior VP & Head of Research5.8yrsVeri yokVeri yok
Charlie Qi
Senior Vice President of Global Clinical Development1.8yrsVeri yokVeri yok
Xichen Zhang
Senior Vice President of Manufacturing & Quality2.8yrsVeri yokVeri yok
Wen-I Chang
Senior Vice President of Oncology Franchise Strategy2.6yrsVeri yokVeri yok
Caroline Germa
Executive VP of Global Medicine Development & Chief Medical Officer2.3yrsVeri yokVeri yok
Kwan Wai Leung
Company Secretary3.4yrsVeri yokVeri yok

2.8yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: 6628's management team is considered experienced (2.8 years average tenure).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Xueming Qian
CEO & Executive Chairman12.1yrsCN¥5.56m12.71%
HK$ 52.0m
Briggs W. Morrison
Chairman of Scientific Advisory Boardno dataVeri yokVeri yok
Pasi Antero Janne
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Kumar Srinivasan
Independent Non-Executive Director1.9yrsCN¥226.00kVeri yok
Ling Su
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Wei Chen
Independent Non-Executive Director1.3yrsCN¥72.00kVeri yok
Susan M. Jerian
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Li Xu
Member of Scientific Advisory Board3.8yrsVeri yok0.18%
HK$ 727.1k
Jiasong Tang
Independent Non-Executive Director3.2yrsCN¥219.00kVeri yok
Zhihua Zhang
Independent Non-Executive Director3.2yrsCN¥219.00kVeri yok

3.2yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 6628's board of directors are considered experienced (3.2 years average tenure).